Saturday, September 23, 2023
Saturday, September 23, 2023

MD Orthopaedics Publishes Clubfoot Chronicles, One Parent’s Heartfelt and Personal Account of Life With a Clubfoot Child

MD Orthopaedics, manufacturer of the gold-standard Mitchell Ponseti® orthotic solutions for the treatment of clubfoot, announces publication of the new book Clubfoot Chronicles, written by Brand Ambassador Maureen Hoff.

Clubfoot Chronicles offers an honest and heartfelt look into the ups and downs of raising a clubfoot child. While the physician plays a key role in the manipulation and casting portion of treatment, up to 95% of clubfoot treatment is managed – at home – by the parents. New parents can quickly be overwhelmed with the demands of weekly doctor’s visits, the heavy casts, implementing daily stretches, checking that the casts and boots fit properly and simply managing the care of a newborn, especially if there are other children at home.

Upon hearing her daughter’s clubfoot diagnosis, Maureen set out to find out as much as she could about the clubfoot defect and treatment options. She spent hours on the computer, finding plenty of information about the casting phase, but very little about the bracing phase of treatment – also known as the boots-and-bar phase. This is arguably the most critical part of treatment, as non-compliance with the prescribed bracing protocol can lead to relapse of the clubfoot, but there is little information available to help uncertain parents manage this critical piece of their child’s care. It was this struggle to find the information and resources she was looking for that motivated Maureen to write the book, so that other clubfoot parents would not face the same difficulties.

Clubfoot Chronicles tells the story of Maureen’s personal struggles in caring for her child and the fear, anxiety, and stress she felt trying to manage her daughter’s care. With brutal honesty, Maureen shines a light on the many challenges clubfoot parents face and shares the many resources she uncovered that helped her cope. It is her hope that other clubfoot parents will benefit from her experiences, wisdom and research and have a smoother, easier clubfoot journey.

Maureen Hoff has her master’s degree in Marriage and Family Therapy and is passionate about clubfoot advocacy, specifically providing support and resources for other clubfoot parents. She is the mother of 3 smart and sassy girls, the last of which was born with bilateral clubfoot in 2018. Maureen recently became a Brand Ambassador for MD Orthopaedics and is working with them to create supportive content for other clubfoot parents.

Clubfoot is one of the most common musculoskeletal birth defects, affecting one out of every 100 babies born worldwide. The non-surgical Ponseti Method is the gold standard treatment, used to remedy approximately 95% of clubfoot cases worldwide. This Method is safer, less expensive, and more effective, using weekly manipulation and casting of the clubfoot to “train” it to the proper position. After the casting phase is complete, the child is fitted with an ankle-foot orthotic (AFO) to keep the manipulated foot in position. The AFO is worn for 23 hours a day for three months, then during nap and overnight sleep time for up to five years.

Clubfoot Chronicles is available in e-book format on Amazon:

The book is also available from Amazon in paperback:

The paperback will also be available at Home – MD Orthopaedics – ( beginning in mid-July.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures. Receives FDA Clearance and Breakthrough Device Designation has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy